Request Demo
Last update 22 Mar 2025
Pamvatamig
Last update 22 Mar 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms MCLA 129, MCLA-129 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 43197L
Source: *****
Sequence Code 1118157432H
Source: *****
Sequence Code 1118157433H
Source: *****
Related
7
Clinical Trials associated with PamvatamigNCT06885840
A Multi-cohort, Open-label Phase II Study to Evaluate the Efficacy and Safety of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Gene Alterations and MET Amplification.
This is a multi-center, open-label, phase II clinical study of MCLA-129 as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with actionable gene alterations and MET amplification to evaluate the efficacy, safety, pharmacokinetic characteristics of MCLA-129.
Start Date31 Mar 2025 |
Sponsor / Collaborator |
CTR20232478
抗EGFR/c-Met双特异性抗体MCLA-129联合贝福替尼在EGFR敏感突变晚期非小细胞肺癌患者中进行的评价安全性、药代动力学特征和抗肿瘤活性的I期临床研究
[Translation] A phase I clinical study of the anti-EGFR/c-Met bispecific antibody MCLA-129 combined with befortinib in patients with advanced non-small cell lung cancer with EGFR sensitive mutations to evaluate safety, pharmacokinetic characteristics and anti-tumor activity
评价MCLA-129联合贝福替尼在EGFR敏感突变晚期非小细胞肺癌患者中的安全性和耐受性，确定可能出现的剂量限制性毒性（DLT）和最大耐受剂量（MTD）；确定推荐II期联合剂量（RP2CD）；评价MCLA-129联合贝福替尼在晚期实体瘤患者中的药代动力学（PK）特征；评价MCLA-129的免疫原性；评价MCLA-129联合贝福替尼在EGFR敏感突变晚期非小细胞肺癌患者中RP2CD下的疗效和安全性
[Translation]
To evaluate the safety and tolerability of MCLA-129 combined with befortinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations, determine the possible dose-limiting toxicity (DLT) and maximum tolerated dose (MTD); determine the recommended Phase II combination dose (RP2CD); evaluate the pharmacokinetic (PK) characteristics of MCLA-129 combined with befortinib in patients with advanced solid tumors; evaluate the immunogenicity of MCLA-129; evaluate the efficacy and safety of MCLA-129 combined with befortinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations under RP2CD
Start Date19 Sep 2023 |
Sponsor / Collaborator |
NCT06015568
Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity
To evaluate the safety and tolerance of MCLA-129 combined with Befotertinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations.
Start Date01 Sep 2023 |
Sponsor / Collaborator |
100 Clinical Results associated with Pamvatamig
Login to view more data
100 Translational Medicine associated with Pamvatamig
Login to view more data
100 Patents (Medical) associated with Pamvatamig
Login to view more data
25
News (Medical) associated with Pamvatamig11 Mar 2025
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader approvals for early-stage treatment all contribute to its promising growth potential.
LAS VEGAS , March 11, 2025 /PRNewswire/ -- DelveInsight's "
TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) at approximately nine-fold lower concentrations than wild-type. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of TAGRISSO. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
AstraZeneca's TAGRISSO (osimertinib) Overview
TAGRISSO is a prescription medication for adults with non-small cell lung cancer (NSCLC) that carries specific EGFR gene mutations. It is used to help prevent cancer recurrence after surgical tumor removal, as a first-line treatment for metastatic NSCLC, or for patients whose cancer has spread and no longer responds to prior EGFR TKI therapy.
As a kinase inhibitor, TAGRISSO irreversibly targets specific mutant forms of EGFR (T790M, L858R, and exon 19 deletions) with significantly higher selectivity than the wild-type EGFR. After oral administration, two active metabolites (AZ7550 and AZ5104) circulate at around 10% of the parent drug and exhibit similar inhibitory effects as osimertinib. In vitro studies also show that osimertinib inhibits HER2, HER3, HER4, ACK1, and BLK at clinically relevant levels.
The recommended TAGRISSO dosage is 80 mg once daily, taken with or without food, and continued until disease progression or unacceptable toxicity occurs.
Learn more about TAGRISSO projected market size for EGFR mNSCLC @
TAGRISSO Market Potential
EGFR is a protein that plays a crucial role in cell growth. When mutations occur in the EGFR gene, they can lead to excessive cell growth, potentially causing cancer. These mutations can take various forms, including deletions, insertions, and point mutations. Among the most common EGFR mutations detected in test results are the EGFR exon 19 deletion and the EGFR L858R point mutation.
In non-small cell lung cancer, targeted therapies primarily focus on EGFR-sensitizing mutations and EGFR exon 20 insertions. The most frequently observed EGFR mutations include exon 19 deletions and exon 21 L858R mutations. To address these, the FDA has approved several tyrosine kinase inhibitors (TKIs).
In 2023, the EGFR-mutated NSCLC market across the 7MM was valued at approximately
USD 4 billion. The NSCLC treatment landscape is becoming increasingly biomarker-driven, with EGFR emerging as one of the most lucrative targets.
TAGRISSO remains the leading therapy in this segment, maintaining a strong market presence. However, resistance to EGFR TKIs, particularly after TAGRISSO treatment, is a growing challenge. Developing treatments for patients who experience resistance remains one of the most pressing unmet needs in this space.
Discover more about the EGFR mNSCLC market in detail @
EGFR Metastatic Non-small Cell Lung Cancer Market Report
Emerging Competitors of TAGRISSO
The promising candidates in EGFR NSCLC pipeline include
Patritumab deruxtecan (Daiichi Sankyo/AstraZeneca),
Zipalertinib (Cullinan Oncology/Taiho Pharma),
Aumolertinib/Almonertinib/HS-10206 (Jiangsu Hansoh Pharmaceutical),
Savolitinib (AstraZeneca/Hutchison MediPharma),
Ivonescimab (AK112/SMT112) (Akeso Biopharma/Summit Therapeutics),
Firmonertinib (ArriVent BioPharma),
Sunvozertinib (DZD9008) (Dizal Pharmaceutical),
BNT327/PM8002 (Biotheus/BioNTech),
Zanidatamab (Jazz Pharmaceuticals),
TAS3351 (Taiho Oncology),
H002 (RedCloud Bio),
JIN-A02 (J INTS BIO),
FWD1509 (Forward Pharma),
Sasanlimab (Pfizer),
Pamvatamig (MCLA-129) (Merus),
REQORSA (quaratusugene ozeplasmid) (Genprex),
PT-112 (Promontory Therapeutics),
HMBD-001 (Hummingbird Bioscience),
PLB1004 (Avistone Biotechnology),
Carotuximab (ENV-105) (Kairos Pharma), and others.
To know more about the number of competing drugs in development, visit @
TAGRISSO Market Positioning Compared to Other Drugs
Key Milestones of TAGRISSO
In
December 2024, TAGRISSO was approved in Europe for patients with unresectable EGFR-mutated lung cancer based on the results of the LAURA Phase III study.
In
September 2024, TAGRISSO was approved in the US for patients with unresectable stage III EGFR-mutated lung cancer based on LAURA Phase III trial results.
In
July 2024, TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, was approved in Europe for the first-line treatment of adult patients with advanced EGFR-mutated NSCLC whose tumors have exon 19 deletions or exon 21 (L858R) mutations. Approval was based on the results from the Phase III FLAURA2 study.
In
June 2024, TAGRISSO in combination with chemotherapy was approved in Japan as a first-line treatment for patients with EGFR-mutated advanced lung cancer based on Phase III FLAURA2 results.
In
June 2024, TAGRISSO was granted priority review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer. TAGRISSO was also recently granted BTD by the FDA in this setting.
In
February 2024, TAGRISSO in combination with chemotherapy was approved in the US for patients with EGFR-mutated advanced lung cancer based on Phase III FLAURA2 results.
In
October 2023, TAGRISSO plus chemotherapy was granted priority review in the US for patients with EGFR-mutated advanced lung cancer based on FLAURA2 Phase III trial results.
In
August 2022, TAGRISSO was approved in Japan for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer based on the positive results from the global ADAURA Phase III trial.
In
May 2021, TAGRISSO was approved in Europe for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer based on unprecedented results from the ADAURA Phase III trial.
In
December 2020, TAGRISSO was approved in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer based on unprecedented results from the ADAURA Phase III trial.
In
October 2020, TAGRISSO granted priority review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer based on the data from the ADAURA Phase III trial.
In
July 2020, TAGRISSO was granted BTD in the US for the adjuvant treatment of patients with Stage IB–IIIA EGFR-mutated lung cancer based on unprecedented results from the Phase III ADAURA trial.
In
August 2018, the MHLW approved TAGRISSO for the first-line treatment of patients with inoperable or recurrent EGFR mutation-positive NSCLC
In
June 2018, the EC granted marketing authorization for TAGRISSO as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
In
April 2018, the US FDA approved TAGRISSO for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
In
April 2018, Molecular Partners and AstraZeneca announced a clinical collaboration for MP0250 in EGFR-mutated NSCLC with osimertinib. Under the collaboration, AstraZeneca will supply osimertinib for the clinical study.
In
April 2017, the EC granted full marketing authorization for TAGRISSO for treating adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
In
March 2017, the US FDA granted full approval for TAGRISSO for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after an EGFR TKI therapy. TAGRISSO was granted accelerated approval for this indication in November 2015 based on tumor response rate and duration of response.
In
2017, TAGRISSO was granted BTD and priority review by the US FDA for the first-line treatment of patients with metastatic NSCLC.
In
March 2016, the MHLW approved TAGRISSO for the treatment of patients with EGFR T790M mutation-positive inoperable or recurrent NSCLC that is resistant to EGFR-TKI.
In
January 2016, AstraZeneca and Incyte Corporation announced a clinical trial collaboration to evaluate the efficacy and safety of INCB39110 in combination with osimertinib.
In
September 2014, the US FDA granted ODD to TAGRISSO for treating EGFR mutation-positive NSCLC.
In
April 2014, TAGRISSO received BTD from the US FDA for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after an EGFR TKI therapy.
In
November 2013, TAGRISSO was granted FTD for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after an EGFR TKI therapy.
Discover how TAGRISSO is shaping the EGFR NSCLC treatment landscape @
TAGRISSO NSCLC
TAGRISSO Market Dynamics
TAGRISSO, developed by AstraZeneca, is a third-generation EGFR TKI that has become a key player in the treatment of
NSCLC with EGFR mutations. Since its approval, TAGRISSO has gained significant traction due to its
efficacy in treating both first-line and post-resistance settings, particularly in patients with the T790M resistance mutation. The drug's ability to penetrate the
blood-brain barrier and show strong efficacy against brain metastases has further strengthened its market positioning, leading to widespread adoption among oncologists.
A major driver of TAGRISSO's market dynamics is its dominance as the preferred
first-line treatment for EGFR-mutated NSCLC. This shift from earlier-generation TKIs has been supported by clinical data demonstrating
superior progression-free survival (PFS) and overall survival (OS) benefits. The expansion of TAGRISSO's indications, including its approval in the
adjuvant setting for early-stage EGFR-mutated NSCLC, has further broadened its market reach. Additionally, AstraZeneca has aggressively pursued
global regulatory approvals, ensuring market access across multiple geographies, particularly in high-prevalence regions such as East Asia, where EGFR mutations are more common.
However, TAGRISSO faces growing challenges, including the
emergence of resistance mechanisms such as MET amplification and C797S mutations, which limit long-term efficacy. To counteract this, AstraZeneca is exploring combination strategies with MET inhibitors and other targeted therapies. Furthermore,
increasing competition from next-generation EGFR TKIs, such as those under development by companies like Takeda and Johnson & Johnson, poses a potential threat.
Pricing and reimbursement pressures, particularly in cost-sensitive markets, also impact its commercial strategy, necessitating a balance between pricing optimization and maintaining accessibility.
Despite these challenges, TAGRISSO remains a blockbuster drug with robust revenue growth, driven by
strong clinical performance and strategic lifecycle management. Ongoing clinical trials evaluating its use in
earlier disease stages and in combination therapies could further extend its market leadership. With its strong foothold in the EGFR-mutated NSCLC landscape, TAGRISSO is expected to remain a
key driver of AstraZeneca's oncology portfolio in the foreseeable future.
Dive deeper to get more insight into TAGRISSO's strengths & weaknesses relative to competitors @
TAGRISSO Market Drug Report
Table of Contents
Related Reports
EGFR Non-small Cell Lung Cancer Market
EGFR Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key EGFR NSCLC companies, including
AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Eli Lilly, Hansoh Pharmaceutical, J&J Innovative Medicine, Pfizer, Cullinan Oncology, Taiho Pharmaceutical, ArriVent Biopharma, Black Diamond Therapeutics, Daiichi Sankyo, Black Diamond Therapeutic, J INTS BIO, NALO Therapeutics, Scorpion Therapeutics, ORIC Pharmaceuticals, among others.
EGFR Non-small Cell Lung Cancer Pipeline
EGFR Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key EGFR non-small cell lung cancer companies, including
Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics, among others.
Non-small Cell Lung Cancer Market
Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including
Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality biologics, among others.
Non-small Cell Lung Cancer Pipeline
Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including
BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
Drug ApprovalPhase 3Priority ReviewAccelerated ApprovalASCO
06 Mar 2025
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but TEPMETKO's once-daily dosing and efficacy profile offer differentiation.
LAS VEGAS, March 6, 2025 /PRNewswire/ -- DelveInsight's "
TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase inhibitor indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of TEPMETKO. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
EMD Serono's TEPMETKO (tepotinib) Overview
TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as hydrochloride monohydrate), administered orally. Patients should be cautioned about the heightened risk of severe or fatal interstitial lung disease/pneumonitis, liver toxicity, and potential embryo-fetal toxicity, necessitating effective contraception during and shortly after treatment.
Tepotinib specifically targets MET, including variants with exon 14 skipping mutations. It blocks HGF-dependent and independent MET phosphorylation, disrupting MET-driven signaling pathways. Additionally, at clinically relevant concentrations, Tepotinib inhibits melatonin 2 and imidazoline 1 receptors. In vitro studies show that it suppresses tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent cancer cells. In mouse models with MET-driven tumors, including those with MET exon 14 skipping alterations, Tepotinib reduced tumor growth, sustained MET phosphorylation inhibition, and, in one case, decreased metastasis formation.
The recommended dose of TEPMETKO is 450 mg taken orally once daily until disease progression or intolerable toxicity occurs. Patients should take it at the same time each day, swallowing tablets whole without chewing, crushing, or splitting them. If a dose is missed and less than eight hours remain until the next scheduled dose, patients should skip it. In cases of vomiting after taking TEPMETKO, the next dose should be taken at the usual time.
Learn more about TEPMETKO projected market size for NSCLC @
TEPMETKO Market Potential
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 81% of all diagnosed cases. Early detection greatly improves outcomes, but diagnosing NSCLC and other lung cancers is challenging because their symptoms are often mistaken for common illnesses or the long-term effects of smoking. Consequently,
80% of NSCLC cases are already at advanced stages by the time they are identified, making treatment more difficult. Around
80% of EGFR mutations in NSCLC involve either exon 19 deletions or the exon 21 L858R substitution, both of which are classified as sensitizing mutations.
Until the last decade, chemotherapy was the primary treatment for advanced and metastatic lung cancer. However, this changed in 2015 with the approval of the first immune checkpoint inhibitor (ICI),
KEYTRUDA (pembrolizumab), as a second-line therapy for advanced cases. This was followed by
TECENTRIQ (atezolizumab) in 2016. Both therapies were later approved for first-line treatment, broadening their use to a larger patient population. In 2020, the combination of
OPDIVO (nivolumab) and ipilimumab also received approval as a first-line treatment for metastatic NSCLC.
According to DelveInsight, the NSCLC market size across the 7MM is projected to grow from
USD 30 billion in 2024, with a substantial CAGR through 2034. This growth is largely driven by the introduction of emerging therapies during the forecast period (2025–2034).
Discover more about the NSCLC market in detail @
Non-small Cell Lung Cancer Market Report
Emerging Competitors of TEPMETKO
The NSCLC pipeline is very robust with the promising therapies such as
Telisotuzumab vedotin (AbbVie),
Patritumab deruxtecan (Daiichi Sankyo/AstraZeneca),
Datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca),
Eftilagimod alpha (Immutep),
BNT311/GEN1046 (acasunlimab) (Genmab),
V940 (mRNA-4157) + Pembrolizumab (Moderna Therapeutics/Merck),
Plinabulin + Docetaxel (BeyondSpring),
Olomorasib (LY3537982) (Eli Lilly and Company),
Zipalertinib (Cullinan Oncology/Taiho Pharma),
Ceralasertib (AZD6738) (AstraZeneca),
TEDOPI (EP-2101; IDM 2101; OSE-2101) (OSE Immuno-therapeutics),
Sigvotatug vedotin
(PF08046047) (Pfizer),
ANKTIVA (N-803) (ImmunityBio),
Aumolertinib/Almonertinib/HS-10206 (Jiangsu Hansoh Pharmaceutical),
Niraparib (GSK),
Savolitinib (AstraZeneca/Hutchison MediPharma),
TRODELVY (Gilead Sciences),
Pyrotinib (Jiangsu HengRui Medicine),
Ociperlimab (BGB-A1217) (BieGene),
Volrustomig (AstraZeneca),
Gotistobart (BNT316/ONC-392) (OncoC4/BioNTech),
Ivonescimab (AK112/SMT112) (Akeso Biopharma/Summit Therapeutics),
ZYNYZ (retifanlimab/INCMGA00012) (Incyte/Macrogenics),
Divarasib (GDC-6036) (Roche/Genentech),
Tiragolumab (RG6058) (Roche),
Sacituzumab Tirumotecan (Merck and Kelun-Biotech),
JEMPERLI (dostarlimab/TSR-042) (GSK and AnaptysBio),
Zongertinib (BI-1810631) (Boehringer Ingelheim),
BAY 2927088 (Bayer),
Serplulimab (HLX10) (Shanghai Henlius Biotech),
Rilvegostomig (AZD2936) (AstraZeneca),
MK-1084 (Merck, Taiho Pharmaceutical, and Astex),
Domvanalimab (Arcus Biosciences and Gilead Sciences),
OPDUALAG (nivolumab and relatlimab) (Bristol-Myers Squibb),
Belrestotug + JEMPERLI (iTeos Therapeutics and GSK),
Firmonertinib (ArriVent BioPharma),
Sunvozertinib (DZD9008) (Dizal Pharmaceutical),
Cobolimab (GSK),
Livmoniplimab (AbbVie),
Fianlimab (REGN3767) (Regeneron Pharmaceuticals),
BNT327/PM8002 (Biotheus/BioNTech),
HS-20117 (Hansoh BioMedical),
IO102-IO103 + Pembrolizumab (IO Biotech),
Naptumomab estafenatox (NeoTX Therapeutics/Active Biotech),
FF-10832 (FUJIFILM Corporation),
BNT116 (BioNTechSE/Regeneron Pharmaceuticals),
CAN-2409 (Candel Therapeutics),
Mecbotamab Vedotin (BA3011/CAB-AXL-ADC) (BioAtla),
Bemcentinib (BGB 324/BGB-3234/R-428) (BerGenBio/Rigel Pharmaceuticals),
DOVBLERON (taletrectinib/AB-106/IBI-344) (Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku),
Lifileucel (Iovance Biotherapeutics),
IBI363 (Innovent Biologics),
Sotevtamab (AB-16B5) (Alethia Biotherapeutics),
Avutometinib (VS6766) (Verastem Oncology),
Vebreltinib (APL-101) (Apollomics),
LP-300 (Lantern Pharma),
JNJ-90301900 (Johnson & Johnson Innovative Medicine),
AMG 193 (Amgen),
Luveltamab tazevibulin (Sutro Biopharma),
PRT3789 (Prelude Therapeutics),
Disitamab vedotin (Seagen),
PADCEV (enfortumab vedotin) (Astellas Pharma),
RP1 (Replimune),
TIVDAK (tisotumab vedotin) (Seagen),
Zanidatamab (Jazz Pharmaceuticals),
Utidelone injectable
(UTD1) (Beijing Biostar Pharmaceuticals),
REGN5093-M114 (Regeneron Pharmaceuticals),
SLC-391 (SignalChem Lifesciences),
fulzerasib (GenFleet),
Davutamig (REGN5093) (Regeneron Pharmaceuticals),
TAS3351 (Taiho Oncology),
H002 (RedCloud Bio),
JIN-A02 (J INTS BIO),
FWD1509 (Forward Pharma),
Sabestomig (AZD7789) (AstraZeneca),
Sasanlimab (Pfizer),
Selvigaltin (GB1211) (Galecto Biotech),
Vepafestinib Helsinn (Healthcare/Taiho Pharmaceutical),
EP0031 (A400/ KL590586) (Ellipses Pharma/Kelun-Biotech),
Pamvatamig (MCLA-129) (Merus),
Zidesamtinib (NVL-520) (Nuvalent),
NVL-655 (Nuvalent),
RMC-4630 (Revolution Medicines),
REQORSA (quaratusugene ozeplasmid) (Genprex),
PDC*lung01 (PDC*line Pharma),
Evalstotug (BA3071) (BioAtla and BeiGene),
PT-112 (Promontory Therapeutics),
MRT-2359 (Monte Rosa Therapeutics),
GAIA-102 (GAIA BioMedicine),
Rigosertib (Traws Pharma),
HMBD-001 (Hummingbird Bioscience),
PLB1004 (Avistone Biotechnology),
ANS03 (Avistone Biotechnology),
MYTX-011 (Mythic Therapeutics),
A166 (Sichuan Kelun-Biotech Bio-pharmaceutical),
Atamparib (BN-2397) (Ribon Therapeutics),
DELTACEL (KB-GDT-01) (Kiromic BioPharma),
Carotuximab (ENV-105) (Kairos Pharma),
YL202 (MediLink Therapeutics), and others.
To know more about the number of competing drugs in development, visit @
TEPMETKO Market Positioning Compared to Other Drugs
Key Milestones of TEPMETKO
In
February 2024, the FDA granted traditional approval to TEPMETKO for adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations.
In
February 2022, the EC approved TEPMETKO as monotherapy for the treatment of adult patients with advanced NSCLC harboring alterations leading to METex14 skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
In
February 2021, Merck announced that the US FDA has approved TEPMETKO following priority review for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. This indication was approved under accelerated approval based on ORR and DOR.
In
October 2020, TEPMETKO received ODD for treating NSCLC with MET genomic tumor aberrations
In
March 2020, EMD Serono (the biopharmaceutical business of Merck KGaA), announced that the MHLW approved TEPMETKO for the treatment of patients with unresectable, advanced, or recurrent NSCLC with METex14 skipping alterations.
In
September 2019, the US FDA granted BTD for tepotinib in patients with metastatic NSCLC harboring METex14 skipping alterations who progressed following platinum-based cancer therapy
Discover how TEPMETKO is shaping the NSCLC treatment landscape @
TEPMETKO NSCLC
TEPMETKO Market Dynamics
TEPMETKO competes in a growing but highly specialized market where MET-targeted therapies are gaining traction due to their
efficacy in addressing MET-altered tumors. The market for MET inhibitors is expanding as precision oncology advances and molecular diagnostics become more widely available,
enabling better identification of patients who would benefit from targeted treatments like TEPMETKO.
A key factor shaping TEPMETKO's market dynamics is competition. It directly competes with
Novartis' TABRECTA (capmatinib), another MET inhibitor approved for the same indication. While TEPMETKO offers the advantage of
once-daily dosing compared to TABRECTA's
twice-daily regimen, both drugs have similar efficacy profiles, making physician and patient preference an important differentiator. Additionally,
broader competition from next-generation MET inhibitors and combination therapies in clinical trials could impact TEPMETKO's long-term market position.
Regulatory approvals and market access play a crucial role in TEPMETKO's adoption. The drug has been approved in multiple regions, including the U.S., Europe, and Japan, but
reimbursement and pricing strategies vary by market. Payer policies, along with the
cost-benefit analysis of MET inhibitors compared to other targeted therapies, influence prescription trends. Furthermore,
real-world evidence and post-marketing studies will be critical in demonstrating TEPMETKO's sustained effectiveness and safety, which could support expanded indications and increased market penetration.
Looking ahead, the MET inhibitor market is expected to grow with advances in biomarker-driven therapy, further refining patient selection. TEPMETKO's success will depend on
continued clinical development, potential label expansions, and strategic partnerships to strengthen its competitive edge. As new entrants emerge, Merck KGaA's ability to differentiate TEPMETKO through combination strategies or enhanced formulations may determine its long-term sustainability in this evolving landscape.
Dive deeper to get more insight into TEPMETKO's strengths & weaknesses relative to competitors @
TEPMETKO Market Drug Report
Table of Contents
Related Reports
Non-small Cell Lung Cancer Market
Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including
Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality biologics, among others.
Non-small Cell Lung Cancer Pipeline
Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including
BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others.
C-MET Metastatic Non-small Cell Lung Cancer Market
C-MET Metastatic Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key C-MET mNSCLC companies, including
Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma, among others.
C-MET Non-small Cell Lung Cancer Pipeline
C-MET Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key C-MET non-small cell lung cancer companies, including
AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
Drug ApprovalImmunotherapyPriority Review
27 Feb 2025
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25
- Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25
- Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the fourth quarter and full year and provided a business update.
“We believe that petosemtamab’s receipt of two Breakthrough Therapy designations by the FDA – previously as monotherapy in the 2L+ treatment of r/m HNSCC and very recently, based on updated clinical efficacy, durability and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC, indicates the potential for these treatment regimens to demonstrate substantial improvement over available therapies,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “We look forward to sharing the updated clinical data, including durability, for petosemtamab with pembrolizumab in 1L PD-L1+ r/m HNSCC, for the full phase 2 cohort, in the first half of 2025.”
Petosemtamab (MCLA-158: EGFR x LGR5 Biclonics®): Solid TumorsLiGeR-HN1 phase 3 trial in 1L PD-L1+ r/m head and neck squamous cell carcinoma (HNSCC) and LiGeR-HN2 phase 3 trial in 2/3L r/m HNSCC enrolling – we expect both trials to be substantially enrolled by YE25; clinical update on phase 2 trial in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC planned for 1H25; phase 2 trial in 1L, 2L and 3L+ metastatic colorectal cancer (mCRC) enrolling; mCRC initial clinical data planned for 2H25
In February 2025 , the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) for petosemtamab in combination with pembrolizumab for the first-line treatment of adult patients with r/m PD-L1+ HNSCC with CPS ≥ 1. This designation was detailed in our press release, Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma ( February 18 , 2025).
In September 2024 , Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC compared to pembrolizumab. In this trial, patients will be randomized to petosemtamab plus pembrolizumab or pembrolizumab monotherapy. This was detailed in our press release, Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC ( September 30 , 2024).
Merus provided an interim clinical update on petosemtamab with pembrolizumab in 1L PD-L1+ r/m HNSCC at the American Society of Clinical Oncology ® (ASCO®) Annual Meeting 2024, demonstrating a 67% response rate among 24 evaluable patients. The oral presentation was detailed in our press release, Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC ( May 28, 2024 ). A clinical update on this cohort is planned for 1H25.
In July 2024 , Merus announced the first patient was dosed in LiGeR-HN2, a phase 3 trial evaluating the efficacy and safety of petosemtamab in 2/3L HNSCC compared to standard of care. In this trial, patients will be randomized to petosemtamab monotherapy or investigator’s choice of single agent chemotherapy or cetuximab. This was detailed in our press release, Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC - Merus ( July 24 , 2024).
Merus provided updated interim clinical data on petosemtamab in 2L+ r/m HNSCC at the European Society for Medical Oncology Asia Congress , demonstrating a 36% response rate among 75 evaluable patients. The oral presentation was detailed in our press release, Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC ( Dec. 7 , 2024).
In May 2024 , the FDA granted BTD for petosemtamab for the treatment of patients with recurrent or metastatic HNSCC whose disease has progressed following treatment with platinum based chemotherapy and an anti-programmed cell death receptor-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody. This designation was detailed in our press release, Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA ( May 13 , 2024).
Merus believes a randomized registration trial in HNSCC with an overall response rate endpoint could potentially support accelerated approval and the overall survival results from the same study could potentially verify its clinical benefit to support regular approval.
In the third quarter 2024, Merus announced the first patient was dosed in a phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 2L mCRC. This was detailed in our press release, Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC ( July 8, 2024 ). In the fourth quarter 2024, Merus announced the first patient was dosed in a phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) mCRC. This was detailed in our press release, Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC ( Dec. 16, 2024 ). In January 2025 , the first patient was dosed in a phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 1L mCRC. We expect to provide initial clinical data for petosemtamab in mCRC in 2H25.
BIZENGRI® (zenocutuzumab-zbco: HER2 x HER3 Biclonics®)Approved by FDA for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy
In December 2024 , the FDA approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or NSCLC that are advanced unresectable or metastatic and harbor a NRG1 gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI® has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD)/pneumonitis, and left ventriculardysfunction.1 See Important Safety Information below. This was detailed in our press release, Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study ( December 4 , 2024).
Merus has exclusively licensed to Partner Therapeutics the right to commercialize BIZENGRI® for the treatment of NRG1+ cancer in the U.S. This was detailed in our press release, Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer ( December 2 , 2024).
MCLA-129 (EGFR x c-MET Biclonics®): Solid Tumors
Investigation of MCLA-129 is ongoing in METex14 NSCLC; phase 2 trial in combination with chemotherapy in 2L+ EGFR mutant (EGFRm) NSCLC enrolling
In the third quarter 2024, Merus announced the first patients were dosed in the phase 2 trial evaluating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC, with a cohort receiving MCLA-129 and paclitaxel and carboplatin, and another cohort receiving MCLA-129 and docetaxel. We remain interested in partnering MCLA-129 to sufficiently resource the development of MCLA-129 and the potential benefit it may have for patients.
MCLA-129 is subject to a collaboration and license agreement with Betta Pharmaceuticals Co. Ltd. (Betta), which permits Betta to develop MCLA-129, and potentially commercialize exclusively in China, while Merus retains global rights outside of China.
Collaborations
Incyte CorporationSince 2017, Merus has been working with Incyte Corporation (Incyte) under a global collaboration and license agreement focused on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. For each program under the collaboration, Merus receives reimbursement for research activities and is eligible to receive potential development, regulatory and commercial milestones and sales royalties for any products, if approved.
Eli Lilly and CompanyIn January 2021, Merus and Eli Lilly and Company (Lilly) announced a research collaboration and exclusive license agreement to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies utilizing Merus’ Biclonics® platform and proprietary CD3 panel along with the scientific and rational drug design expertise of Lilly. The collaboration is progressing well with three programs advancing through preclinical development.
Gilead SciencesIn March 2024, Merus and Gilead Sciences announced a collaboration to discover novel antibody based trispecific T-cell engagers using Merus’ patented Triclonics® platform. Under the terms of the agreement, Merus will lead early-stage research activities for two programs, with an option to pursue a third. Gilead will have the right to exclusively license programs developed under the collaboration after the completion of select research activities. If Gilead exercises its option to license any such program from the collaboration, Gilead will be responsible for additional research, development and commercialization activities for such program. Merus received an equity investment by Gilead of $25 million in Merus common shares and an upfront payment of $56 million.
Ono PharmaceuticalIn 2018, the Company granted Ono Pharmaceutical Co., Ltd. (Ono) an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market a limited number of bispecific antibody candidates based on Merus’ Biclonics® technology platform directed to an undisclosed target combination. During the third quarter of 2024, Merus achieved and received a milestone payment based on the filing of an Investigational New Drug (IND) application in Japan.
BiohavenIn January 2025 , Merus and Biohaven announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics® technology platform, and Biohaven’s next-generation ADC conjugation and payload platform technologies. Under the terms of the agreement, Biohaven is responsible for the preclinical ADC generation of three Merus bispecific antibodies under mutually agreed research plans. The agreement includes two Merus bispecific programs generated using the Biclonics® platform, and one program under preclinical research by Merus. Each program is subject to mutual agreement for advancement to further development, with the parties then sharing subsequent external development costs and commercialization, if advanced.
Cash Runway, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028
As of December 31, 2024, Merus had $724.0 million cash, cash equivalents and marketable securities. Based on the Company’s current operating plan, the existing cash, cash equivalents and marketable securities are expected to fund Merus’ operations into 2028.
Full Year 2024 Financial Results
Collaboration revenue for the year ended December 31, 2024 decreased $7.8 million as compared to the year ended December 31, 2023 , primarily as a result of decreases in Lilly revenue of $8.4 million and Incyte revenue of $6.4 million , offset by increases in Gilead revenue of $4.8 million , and Other revenue of $2.2 million . The decrease in Lilly revenue is primarily the result of decreases in upfront payment amortization of $4.8 million and reimbursement revenue of $3.6 million . The decrease in Incyte revenue is primarily the result of decreases in milestone revenue of $5.0 million and reimbursement revenue of $1.4 million . Gilead revenue increased due to the start of the collaboration agreement in 2024 which resulted in an increase in upfront payment amortization of $4.8 million . The increase in Other revenue is primarily the result of increases in milestone revenue of $2.1 million .
Research and development expense for the year ended December 31, 2024 increased $84.7 million as compared to the year ended December 31, 2023 , primarily as a result of increases in external clinical services and drug manufacturing costs of $66.6 million , which primarily includes costs to advance our petosemtamab program and costs to fulfill our obligations under our collaboration agreements related to our programs, increases in personnel related expenses including share-based compensation of $11.8 million due to an increase in employee headcount and an increase in share price, consultancy expenses of $5.5 million , facilities expenses and other related expenses of $0.7 million , and consumables expenses of $0.2 million , offset by decreases in depreciation and amortization of $0.1 million .
General and administrative expense for the year ended December 31, 2024 increased $23.0 million as compared to the year ended December 31, 2023 , primarily as a result of increases in personnel related expenses including share-based compensation of $12.6 million due to an increase in employee headcount and an increase in share price, consultancy expenses of $6.8 million , legal expenses of $1.8 million , facilities and depreciation expense of $1.2 million , and intellectual property and licenses expenses of $0.7 million . Other income, net consists of interest earned on our cash and cash equivalents held on account, accretion of investment earnings and net foreign exchange gains or losses on our foreign denominated cash, cash equivalents and marketable securities, and payables and receivables.
Please see full Prescribing Information, including Boxed WARNING, at BIZENGRI.com/pi.
Reference: 1. BIZENGRI. Prescribing information. Merus N.V. ; 2024.
About Merus N.V.
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the content and timing of clinical trials, data readouts and clinical, regulatory, strategy and development updates for our product candidates; our ongoing LiGeR-HN1, LiGeR-HN2 and phase 2 mCRC trials for petosemtamab, our planned update in the 1H 2025 on the phase 2 cohort of 1L r/m PD-L1+ HNSCC; our planned initial clinical data update on the phase 2 investigation of petosemtamab in mCRC; our belief that petosemtamab’s receipt of two BTDs by the FDA – previously as monotherapy in the 2L+ treatment of r/m HNSCC and very recently, based on updated clinical efficacy, durability and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC, indicates the potential for these treatment regimens to demonstrate substantial improvement over available therapies; the potential benefits of BTD for petosemtamab’s development, if any; our looking forward to sharing the updated clinical data, including durability, for petosemtamab with pembrolizumab in 1L PD-L1+ r/m HNSCC, for the full phase 2 cohort, in the first half of 2025; our expectation that the LiGeR-HN1 and LiGeR-HN2 studies will be substantially enrolled by year-end; our belief that a randomized registration trial in HNSCC with an overall response rate endpoint could potentially support accelerated approval and the overall survival results from the same study could potentially verify its clinical benefit to support regular approval; statements regarding the sufficiency of our cash, cash equivalents and marketable securities, and expectation that it will fund the Company into 2028; the continued investigation of MCLA-129 in monotherapy in Met ex14 NSCLC, and enrolling of patients in the investigation of MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC; our interest in partnering MCLA-129 to sufficiently resource the development of MCLA-129 and the potential benefit it may have for patients; the benefits of the license from Merus to PTx for the commercialization of Bizengri® in the US for NRG1+ cancer, collaborations between Incyte and Merus, Lilly and Merus, Gilead and Merus, Biohaven and Merus, and license agreement between Ono and Merus; and the potential of those licenses and collaborations for future value generation, including whether and when Merus will receive any future payments, including milestones or royalties, and the amounts of such payments; whether any programs under the collaboration will be successful; and our collaboration and license agreement with Betta, which permits Betta to develop MCLA-129 and potentially commercialize exclusively in China, while Merus retains full ex-China rights, including any future clinical development by Betta of MCLA-129. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the volatility in the global economy, including global instability, including the ongoing conflicts in Europe and the Middle East; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-K for the period ended December 31, 2024, filed with the Securities and Exchange Commission, or SEC, on February 27, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Bizengri®, Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
Source: Merus N.V.
Phase 2Phase 3License out/inBreakthrough TherapyDrug Approval
100 Deals associated with Pamvatamig
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 31 Mar 2025 | |
| MET gene amplification Non-small Cell Lung Cancer | Phase 2 | China | 20 Mar 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 03 Sep 2021 | |
| Metastatic Colorectal Carcinoma | Phase 2 | China | 03 Sep 2021 | |
| Colorectal Cancer | Phase 2 | United States | 28 Apr 2021 | |
| Colorectal Cancer | Phase 2 | Belgium | 28 Apr 2021 | |
| Colorectal Cancer | Phase 2 | France | 28 Apr 2021 | |
| Colorectal Cancer | Phase 2 | Germany | 28 Apr 2021 | |
| Colorectal Cancer | Phase 2 | Italy | 28 Apr 2021 | |
| Colorectal Cancer | Phase 2 | Netherlands | 28 Apr 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 1/2 | Non-Small Cell Lung Cancer | MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer MET exon 14 skipping | EGFR exon 20 insertion | EGFR | 217 | MCLA-129 1500mg (MET exon 14 skipping mutation) | slfoarrzhl(jlnddvmghn) = lhhsmevtaj bvwsczunqg (jsgywqwgbt, 23.2 - 65.5) View more | Positive | 24 May 2024 | |
MCLA-129 2000mg (MET exon 14 skipping mutation) | slfoarrzhl(jlnddvmghn) = mqhahbrbjv bvwsczunqg (jsgywqwgbt, 2.4 - 30.2) View more | ||||||
NCT04868877 (Biospace) Manual  | Phase 1/2 | 22 | fgazjkltvb(renblbrbdq) = tfrhjnzgnc uracofusxe (lwbajtzktf, 1 - 32) View more | Positive | 03 Dec 2023 | ||
Phase 1/2 | 60 | xogwmflmrs(sdmvszoxhr) = ucasqcfybq vxkchmonhx (ckalqhcowq ) View more | Positive | 03 Dec 2023 | |||
(1L) | xogwmflmrs(sdmvszoxhr) = ajkrybduau vxkchmonhx (ckalqhcowq, 70 - 100) View more | ||||||
Phase 1/2 | 18 | dfewogefov(cofrdptcjy) = cjvxtxpdua fljsfbqzhf (eekzppabhw ) View more | Positive | 02 Dec 2023 | |||
Phase 1/2 | 20 | xscpbjsqjg(zydeukxdgw) = flpcbqhuru pxewzjfkod (idnwfkcwui ) View more | Positive | 12 Oct 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free